Highlights•Solid organ transplantation (SOT) patients or patients with active ADs have been
largely excluded from ICIs clinical trials because of the risk of allograft rejection or severe …

In the past 10 years, immune checkpoint inhibitors (ICIs) have become an additional pillar of
cancer therapy by activating the immune system to treat a number of different malignancies …

Immune-checkpoint inhibitors (ICIs) have dramatically changed the management of
advanced cancers. Designed to enhance the antitumour immune response, they can also …

Immunotherapy is an important armamentarium for cancer treatment nowadays. Apart from
their significant effectiveness in controlling disease they also generate potential severe …

Abstract Introduction Immune checkpoints inhibitors (ICIs) are associated with frequent
immune-related adverse events (irAEs), but patients with preexisting autoimmune disease …

Introduction Patients with pre-existing autoimmune diseases have been excluded from
clinical trials of immune checkpoint inhibitors (ICIs) for cancer. Real-world evidence is …

Immune checkpoint inhibitors have emerged as a remarkable treatment option for diverse
cancer types. However, a significant number of patients on checkpoint inhibitors develop …

Background: Cancer immunotherapy with checkpoint inhibitors (CPIs) is associated with
frequent immune-related adverse events (irAEs) and is often not recommended for patients …

The discovery and approved treatment with immune checkpoint inhibitors (ICIs) for a variety
of cancers has changed dramatically the morbidity and mortality rates for these patients …

Immune checkpoint inhibitor (ICI) is a revolutionary breakthrough in the field of cancer
treatment. Because of dysregulated activation of the immune system, patients with …